Variable efficacy of the non-covalent KRASG12D inhibitor (MRTX-1133) with obesity in murine pancreatic cancer

Sujith Sarvesh, Holly Stephens, Pia Muri, Henry Nnaemeka Ogbonna, Jianqing Zhang, Karen Aikhionbare, Dhana Sekar Reddy Bandi, Cherlene Hardy, Ganji Purnachandra Nagaraju, Bassel F. El-Rayes, Lyse A. Norian, Jeremy B. Foote

Open source

DOI
10.1038/s41698-026-01493-z
Published
2026-06-08
Container
npj Precision Oncology
Publisher
Springer Science and Business Media LLC
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1038/s41698-026-01493-z,
  title = {Variable efficacy of the non-covalent KRASG12D inhibitor (MRTX-1133) with obesity in murine pancreatic cancer},
  author = {Sujith Sarvesh and Holly Stephens and Pia Muri and Henry Nnaemeka Ogbonna and Jianqing Zhang and Karen Aikhionbare and Dhana Sekar Reddy Bandi and Cherlene Hardy and Ganji Purnachandra Nagaraju and Bassel F. El-Rayes and Lyse A. Norian and Jeremy B. Foote},
  year = {2026},
  journal = {npj Precision Oncology},
  doi = {10.1038/s41698-026-01493-z},
  url = {https://doi.org/10.1038/s41698-026-01493-z}
}

RIS

TY  - JOUR
TI  - Variable efficacy of the non-covalent KRASG12D inhibitor (MRTX-1133) with obesity in murine pancreatic cancer
AU  - Sujith Sarvesh
AU  - Holly Stephens
AU  - Pia Muri
AU  - Henry Nnaemeka Ogbonna
AU  - Jianqing Zhang
AU  - Karen Aikhionbare
AU  - Dhana Sekar Reddy Bandi
AU  - Cherlene Hardy
AU  - Ganji Purnachandra Nagaraju
AU  - Bassel F. El-Rayes
AU  - Lyse A. Norian
AU  - Jeremy B. Foote
PY  - 2026
JO  - npj Precision Oncology
DO  - 10.1038/s41698-026-01493-z
UR  - https://doi.org/10.1038/s41698-026-01493-z
ER  - 

APA

Sarvesh, S., Stephens, H., Muri, P., Ogbonna, H. N., Zhang, J., Aikhionbare, K., Bandi, D. S. R., Hardy, C., Nagaraju, G. P., El-Rayes, B. F., Norian, L. A., & Foote, J. B. (2026). Variable efficacy of the non-covalent KRASG12D inhibitor (MRTX-1133) with obesity in murine pancreatic cancer. npj Precision Oncology. https://doi.org/10.1038/s41698-026-01493-z

Source records